Disease characteristics associated with synovitis according to disease duration.
| Characteristic | Patients with Disease Duration, < 5 Years, n = 2421 | Patients with Disease Duration Between 5 and 10 Years, n = 2196 | Patients with Disease Duration > 10 Years, n = 2669 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| With Synovitis, n = 460 | Without Synovitis, n =1961 | p | Stepwise Regression, OR (95%CI) | With Synovitis, n = 345 | Without Synovitis, n = 1851 | p | Stepwise Regression, OR (95% CI) | With Synovitis, n = 386 | Without Synovitis, n = 2283 | p | Stepwise Regression OR (95% CI) | |
| Age, mean ± SD, yrs | 55.5 ± 11 | 56.2 ± 12 | 0.4 | NS | 56.3 ± 14 | 56.8 ± 12 | 0.6 | NS | 60.9 ± 15 | 61.3 ± 16 | 0.5 | NS |
| Females (%) | 368 (80) | 1582 (81) | 0.5 | NS | 306 (89) | 1579 (85) | 0.3 | NS | 355 (92) | 2076 (91) | 0.8 | NS |
| Diffuse cutaneous, subtype, n (%) | 233 (51) | 784 (39) | < 0.0001* | 1.96 (1.45–2.51) | 114 (33) | 521 (28) | 0.002* | NS | 137 (35) | 604 (26) | 0.001* | NS |
| Friction rub, n (%) | 121 (26) | 201 (10) | < 0.0001* | 2.51 (1.87–3.39) | 66 (19) | 147 (8) | < 0.0001* | 1.82 (1.33–2.42) | 104 (27) | 163 (7) | < 0.0001* | 2.84 (2.05–3.93) |
| Joint contracture, n (%) | 214 (46) | 531 (27) | < 0.0001* | 1.75 (1.37–2.24) | 147 (43) | 391 (21) | < 0.0001* | 2.04 (1.53–2.73) | 226 (58) | 755 (33) | < 0.0001* | 1.81 (1.41–2.32) |
| Raynaud phenomenon, n (%) | 433 (94) | 1845 (94) | 0.9 | NS | 329 (95) | 1696 (92) | 0.8 | NS | 382 (99) | 2261 (99) | 0.2 | NS |
| Digital ulceration, n (%) | 162 (35) | 534 (27) | 0.002* | NS | 120 (35) | 520 (28) | 0.005* | NS | 186 (48) | 769 (34) | < 0.0001* | NS |
| Muscle weakness, n (%) | 189 (41) | 505 (26) | < 0.0001* | NS | 127 (37) | 416 (22) | < 0.0001* | 1.73 (1.29–2.30) | 172 (45) | 541 (24) | < 0.0001* | 1.89 (1.47–2.44) |
| Pulmonary fibrosis, n (%) | 178 (29) | 618 (32) | 0.01* | NS | 149 (43) | 655 (35) | 0.0008* | NS | 178 (46) | 829 (36) | 0.0005* | NS |
| Elevated systolic pulmonary artery pressure, n (%) | 155 (34) | 400 (20) | < 0.0001* | 1.81 (1.40–2.32) | 103 (30) | 388 (21) | 0.0001* | NS | 150 (39) | 560 (24) | < 0.0001* | 1.39 (1.07–1.75) |
| Renal crisis, n (%) | 21 (4) | 54 (3) | 0.04* | NS | 15 (4) | 31 (1.5) | 0.02* | NS | 5 (6) | 34 (1.5) | 0.9 | NS |
| Positive antinuclear antibodies, n (%) | 404 (88) | 1701 (87) | 0.8 | NS | 314 (91) | 1704 (92) | 0.8 | NS | 376 (97) | 2118 (93) | 0.2 | NS |
| Positive antitopoisomerease-1 antibodies, n (%) | 202 (44) | 636 (32) | < 0.0001* | NS | 145 (42) | 537 (29) | < 0.0001* | 1.91 (1.42–2.57) | 150 (39) | 623 (27) | 0.0003* | NS |
| Positive anticentromere antibodies, n (%) | 97 (21) | 582 (30) | 0.0008* | NS | 72 (21) | 616 (33) | 0.0003* | NS | 117 (30) | 912 (40) | 0.0001* | NS |
| Elevated CPK, n (%) | 69 (15) | 218 (11) | 0.04* | NS | 34 (10) | 128 (7) | 0.1* | NS | 17 (4) | 115 (5) | 0.1* | NS |
| Elevation of acute- phase reactants, n (%) | 237 (52) | 549 (28) | < 0.001* | 2.29 (1.81–2.90) | 133 (39) | 447 (24) | < 0.0001* | 1.60 (1.20–2.14) | 171 (44) | 616 (27) | < 0.0001* | 1.49 (1.16–1.91) |
| Proteinuria, n (%) | 52 (11) | 128 (6) | 0.0004* | NS | 24 (7) | 99 (5) | 0.2 | NS | 31 (8) | 101 (4) | 0.01* | NS |
NS: not significant; CPK: creatine phosphokinase.
↵* Variables included for the multivariate stepwise logistic regression analysis.